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Abstract: Infection and inflammation may have a crucial role in the pathogenesis of atherosclerosis. This hypothesis is 
supported by an increasing number of reports on the interaction between chronic infection, inflammation, and atherogene-
sis. Assessment of serological and inflammatory markers of infection may be useful adjuncts in identifying those patients 
who are at a higher risk of developing vascular events, and in whom more aggressive treatments might be warranted.  
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INTRODUCTION 
  Cerebrovascular disease (CVD) is the most common life 
threatening neurological condition, and is a major contribu-
tor to morbidity, functional disability and mortality world-
wide.  Recent advances in the treatment of acute ischemic 
stroke offer hope in reducing its devastating effects, but 
these therapies are only offered to a small fraction of stroke 
patients. Hence, effective prevention of recurrence, mortality 
and disability after the initial stroke is especially important 
[1]. The recognition of the role of inflammation in the 
pathogenesis, progression and clinical manifestation of athe-
rosclerosis has resulted in a new generation of vascular re-
search. Indeed, the first cell types to be found within the ar-
terial intima in early atherosclerotic lesions are lymphoid 
cells, macrophages and smooth muscle cells [2,3]. Infections 
with organisms such as Helicobacter pylori (HP), Chlamydia 
pneumoniae (CP), Cytomegalovirus (CMV) and odontopa-
thogens, are potentially treatable emerging atherosclerotic 
risk factors [4]. An increasing number of sero-
epidemiological, pathological, immunological and pharma-
cotherapeutic studies suggest a possible link between these 
organisms and atherosclerosis, arterial thrombosis and 
plaque instability.  
HELICOBACTER PYLORI 
  HP is a gram-negative organism that causes chronic ac-
tive gastric inflammation, which is probably life-long unless 
eradicated
 by antibiotics. HP has been found to be associated  
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with extra-digestive diseases, in particular, vascular disor-
ders (e.g. ischemic heart disease, primary Raynaud’s phe-
nomenon, ischemic stroke) and autoimmune disorders (e.g. 
Henoch-Schönlein purpura, Sjögren's syndrome). Many 
case-control studies have reported a significant association 
between HP seropositivity and coronary heart
 disease (CHD) 
and ischemic electrocardiographic changes, independent of 
conventional risk factors and socioeconomic factors [5,6].  
Possible Pathological Mechanisms 
•  Chronic HP infection can cause a low grade chronic 
inflammatory response, as indicated by raised sero-
logical markers
 including fibrinogen, leukocyte count, 
and C-reactive protein (CRP) [5].  
•  Free radical formation may be important as levels of 
antioxidants have been shown to be decreased in
 sub-
jects with HP infection [7]; this could result in lipid 
peroxidation.
  
•  HP infection produces 60 kDa heat
  shock proteins, 
which have a high degree of sequence homology
 with 
human 60 kDa heat shock proteins; presence of cross-
reacting antibodies to heat shock proteins have been 
shown to be a risk factor
 for carotid atherosclerosis 
[8]. 
•  Platelet activation and aggregation have been detected 
in patients infected with HP [9].  
•  Hyperhomocysteinemia may possibly be indirectly 
related to HP infection because chronic gastritis 
caused by HP infection can lead to vitamin and folate 
deficiency, which in turn result in problems with 
methylation by 5-methyl-tetrahydrofolic acid and an 
accumulation of homocysteine in susceptible patients Microbial Risk Factors of Cardiovascular and Cerebrovascular Diseases  The Open Neurology Journal, 2008, Volume 2    21 
[10]. Homocysteine is toxic to endothelial cells and 
results in vascular lesions and ischemic insults.  
CHLAMYDIA PNEUMONIAE 
  CP is an intracellular gram-negative
 bacterium that com-
monly causes respiratory infections in all
  age groups. Hu-
moral
 antibodies against CP have been found in more than 
half
  of the adult population [11]. IgA antibody may be a 
more reliable than IgG as a marker for chronic chlamydial 
infection [11]. A number of cross-sectional and prospective
 
studies have demonstrated an association between high lev-
els of antibody against CP and CHD [12]. Results from 
many other
 studies also suggest a role for CP in carotid ar-
tery thrombosis [13]
 and CVD [14-19].  
Possible Pathological Mechanisms 
Local Effects 
  CP has been proposed to affect and contribute to the 
mechanisms involved in atherosclerotic disease process. As a 
prerequisite, the pathogenic organism must gain entry into 
the
 cells of the arterial wall. It is hypothesized that CP may 
be phagocytosed by alveolar
  macrophages in the lung and 
transported
 by the blood to the subendothelial region through 
the injured
 arterial endothelium [20]. Macrophages infected 
with CP may promote the inflammatory process of athero-
sclerosis by inducing the production
 of cytokines and lipo-
proteins[20], and degenerating into foam cells .
 CP DNA has 
been detected in atherosclerotic tissues at
 different sites of 
the vascular system.  
Systemic Effects 
•  CP can induce an inflammatory response, as indicated 
by raised CRP, leukocyte count, IL-6, IL-8, tumour 
necrosis factor  (TNF ), and expression of tissue 
factor (factor VIIa antigen) [21,22]. 
•  CP can secrete endotoxin and cause activation  of 
monocytes, monocyte integrins  and monocyte-
derived macrophages [23,24]. 
•  CP infection can activate the nuclear factor for the 
expression of immunoglobulin  light chain in the B-
lymphocytes pathway (nuclear factor-kappa B)
44. 
•  There may be immunological reaction against myosin 
filaments of carotid artery wall smooth muscle cells 
due to antigenic mimicry between heavy chains of 
myosin filaments and specific antigens (40, 42, 52, 
54, 60, 75, 98 kDa) presented on CP outer membrane 
[25]. 
•  Antibodies to chlamydial HSP 60 can cause endothe-
lial cytotoxicity [24]. There is also an antigenic mim-
icry between human and chlamydial HSP 65; one 
prospective population-based study strongly supports 
a potential atherogenic role of persistent CP infection 
due to immune reactions to HSP 65 [26].  
•  CP seropositivity can be associated with endothelial 
dysfunction [27], as indicated by elevated levels of 
soluble endothelial cell adhesion molecules (sCAMs) 
as markers of atherosclerotic activity [28].  
•  CP lipopolysaccharides have been
 found in circulat-
ing immune complexes observed in chronically
  in-
fected patients [14]. These lipopolysaccharides may 
have deleterious effects
 on the coagulation system and 
vascular endothelium. 
•  Persistent CP infection may be associated with
  in-
creased fibrinogen [29], platelet accumulation and 
adhesion [30], thrombin [31], plasminogen activator 
inhibitor [22], and enhanced activity of hemostatic 
and pro-coagulant mediators [30]. 
•  CP infection can cause alteration of cholesterol me-
tabolism and lipid oxidation [23], increased  triglyc-
erides [32], increased lipoprotein (a) levels [29], in-
creased total cholesterol levels [33],  and decreased 
high-density lipoprotein cholesterol levels [32,33]. 
CYTOMEGALOVIRUS 
  CMV, or Human Herpes Virus 5, is a double-stranded 
enveloped DNA virus of the Herpesviridae family. The di-
agnosis of acute CMV infection is usually based on serology. 
Newer methods of diagnosis include the presence of pp65 
antigen in granulocytes from peripheral blood, viral DNA 
detection by PCR, viral mRNA detection by nucleic acid 
sequence-based amplification, conventional cell culture, or 
detection of early antigen fluorescent foci in cultures [34]. 
  The involvement CMV in some cardiovascular condi-
tions is well known. CMV may also be involved in the 
pathogenesis of vasculitis, and when this occurs within the 
central nervous system, it can lead to cerebral infarction 
[35,36]. There is a growing body of knowledge supporting 
the hypothesis that CMV may be involved in the develop-
ment of atherosclerosis [37-40]. Several cross-sectional and 
prospective
 studies have indicated that high titres of antibod-
ies to CMV may be associated with CHD [12]. High anti-
CMV antibody titre not only appears to be associated with 
active CHD, but also an early predictor of atherosclerosis 
[41]. Indeed, CMV infection increases the risk of coronary 
artery restenosis after angioplasty, stent placement or bypass, 
and accelerates cardiac transplant-associated coronary athe-
rosclerosis [42]. On the other hand, results from a number of 
in vivo and in vitro studies may not support this hypothesis 
[43-47]. CMV infections have also been found to signifi-
cantly influence the occurrence of cerebrovascular events in 
patients with baseline asymptomatic carotid lesions [48], or 
those with diabetes [49]. 
Possible Pathological Mechanisms 
•  CMV can cause local inflammation, as indicated by 
the presence of CMV DNA in atheromatous 
plaques
41. Vessel wall colonization by CMV may re-
sult in cytokine induction or antigen stimulation. 
•  CMV infection can be associated with thrombocy-
topenia, thrombotic thrombocytopenic purpura [50], 
and acute arterial and venous thromboembolism [51, 
52].  
•  CMV seropositivity can be associated with endothe-
lial dysfunction and impaired responses to nitric ox-
ide independently of conventional risk factors [53].  
•  Chemokine production and expression of virally en-
coded chemokine receptors have been demonstrated 
in infected smooth muscle cells (SMC), this can lead 
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vessel media to the intima, and culminate in vessel 
narrowing [54]. 
•  Further immunological mechanisms may play a role 
as indicated by a recent study [2] which revealed that, 
during CMV infection, a subset of antibodies directed 
against particular viral proteins cross-reacted with 
normally expressed cell-surface molecules, causing 
apoptotic cell death of non-stressed endothelial cells 
through a mechanism of molecular mimicry. Moreo-
ver, in atherosclerosis, the stress induced in endothe-
lial cells by the CMV infection (or reactivation from 
latency) can lead to the expression of HSP 60. Cross-
reactive anti-CMV antibodies may also amplify the 
endothelial damage by binding surface HSP 60 and 
inducing cytotoxicity. 
ODONTOPATHOGENS 
  Periodontitis is a chronic infection by oral bacteria that 
affect the supporting structures of the teeth. Bacterial popu-
lations attached to dental surface consist of biofilm commu-
nities, sometimes 50-100 cells in thickness and with a bacte-
rial density of up to 10
11 Colony Forming Units/mg, forming 
a very complex ecosystem. This is due, in part, to the non-
shedding surface of the teeth, which allows the development 
of persistent colonization. 
  During the past two decades, there has been an increasing 
interest in the impact of oral health on atherosclerosis and 
subsequent CVD. Exposure to periodontal infection might 
influence the development of coronary [55], carotid and pe-
ripheral vascular disease [56]. Porphyromonas gingivalis and 
Streptococcus sanguis are major pathogens associated with 
periodontitis, and research has shown that these infectious 
agents may influence vascular cell functions by inducing 
thrombus formation, vascular cell proliferation, apoptosis, 
and cell death. A mild to moderate association between pe-
riodontitis and the development of CHD and ischemic CVD 
has been observed [57]. One meta-analysis of prospective 
and retrospective follow-up studies also concluded that 
periodontal disease may increase the risk of cardiovascular 
disease by approximately 20%, and the risk of CVD by al-
most two-fold [57, 58]. 
Possible Pathological Mechanisms 
•  Gram-negative bacterial infection causes an endo-
toxemia. Research so far suggests that neopterin, 
which reflects immune activation of monocytes and 
macrophages, functions as atherogenic effect modify-
ing factor on the effects of endotoxin [59]. It is hy-
pothesized that immune activation via  induction of 
endotoxin hyper-responsiveness determines the 
atherogenic potential of periodontal infections [59]. 
•  Before periodontal treatments, individuals with perio-
dontitis have been found to have higher concentra-
tions of total and low-density lipoprotein cholesterol 
and triglycerides, and lower concentrations of high-
density lipoprotein cholesterol [60].  
•  Periodontitis can induce a peripheral  inflammatory 
and immune response, as evidenced by elevated con-
centrations of CRP and IgA antibodies to periodontal 
pathogens. The prevalence of CVD appears to be 
highest in patients with periodontitis and co-existing 
elevated CRP levels, suggesting that periodontitis 
might increase the risk of vascular disease through ac-
tivating the systemic inflammatory and immune re-
sponses. There may also be a genetic component 
which has as yet not been elucidated. 
•  Porphyromonas gingivitis can cause aggregation of 
human platelets in platelet-rich plasma [61]. 
POTENTIAL THERAPEUTIC OPTIONS 
  There is now some evidence that the microbial risk fac-
tors for vascular disease might be treatable. Several prelimi-
nary interventional studies have found that antibiotic therapy 
might improve the prognosis for patients with coronary heart 
disease [62,63]. Infection of vascular endothelial cells with 
CP increases the expression of pro-atherogenic cytokines 
mediated by the transcription factor nuclear factor (NF)-
kappaB, and NF-kappaB-mediated gene activation represents 
a crucial step in the developmental cycle of CP. One possible 
reason why aspirin is cardio-protective may be that it can 
exert an anti-chlamydial effect from inhibiting CP-induced 
NF-kappaB activation [64]. Macrolides, which are effective 
against Chlamydia pneumoniae, may also have several non-
antibiotic (mostly anti-inflammatory) effects which can con-
tribute towards preventing cardio- and cerebrovascular dis-
eases (see Table 1) [65]. One study found that certain mac-
rolides (roxithromycin and azithromycin) can significantly 
reduce the levels of IL-8 and monocyte chemotactic protein 
(MCP)-1, which in turn may inhibit trans-endothelial migra-
tion (TEM) of neutrophils and monocytes [66]. In another 
prospective study, patients receiving roxithromycin were 
significantly less likely to suffer an acute coronary event at 
30 days [67]. Fong et al. [68] showed that clarithromycin 
administration may modify atherosclerotic lesions by reduc-
ing the likelihood of detecting CP bacteria within the lesions. 
Another crucial development is the emergent role of vaccina-
tion in preventing vascular diseases. Observational studies 
have found that vaccination against influenza may be associ-
ated with a reduced risk of stroke, myocardial infarction, and 
all-cause mortality [69]. Infectious diseases during child-
hood, even those occurring within the first year or two of 
life, may predispose an individual to CHD [70].  
Table 1.  Non-Antibiotic Effects of Macrolides 
Improved endothelial function (azithromycin) 
Antioxidant effects (erythromycin, roxithromycin) 
Decreased von Willebrand factor levels (azithromycin) 
Decreased IL 1, 6 and 8 (azithromycin, clarithromycin, erythromycin, 
roxithromycin) 
Decreased TNF (azithromycin, clarithromycin, erythromycin, 
roxithromycin) 
Decreased granulocyte/monocyte colony-stimulating factor (clarithromy-
cin) 
Decreased monocyte chemotactic protein 1 (azithromycin) 
Decreased E-selectin (azithromycin) 
Decreased CRP (roxithromycin) Microbial Risk Factors of Cardiovascular and Cerebrovascular Diseases  The Open Neurology Journal, 2008, Volume 2    23 
CONCLUSION 
  Infection and inflammation may have a crucial role in the 
pathogenesis of atherosclerosis. Serum markers of HP, CP, 
CMV and odontopathogens may predict the risk of CVD 
even after adjusting of traditional risk factors and socioeco-
nomic status [71]. In the future, assessment of serological 
and inflammatory markers of infection may become useful 
adjuncts in identifying those patients who are at a higher risk 
of developing vascular events, and in whom more aggressive 
treatments might be warranted. However, the effects and cost 
implications of this treatment strategy are largely unknown. 
Vaccination before the initial exposure might be a more 
logical approach, and one such vaccine is currently being 
evaluated for CP [72]. Despite a lack of trial evidence, it is 
recommendable that patients with a previous stroke or at 
high risk of stroke should receive an annual influenza vacci-
nation. Currently, there is insufficient evidence to recom-
mend the routine administration of antibiotics in preventing 
cardio- and cerebrovascular diseases in daily clinical prac-
tice. 
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